MX353177B - Composicion farmaceutica que comprende (1r,4r)-6´-fluoro-n,n-dimet il-4-fenil-4´,9´-dihidro-3´h-espiro[ciclohexan-1,1´-pirano[3,4,b] indol]-4-amina y un anticonvulsivante. - Google Patents
Composicion farmaceutica que comprende (1r,4r)-6´-fluoro-n,n-dimet il-4-fenil-4´,9´-dihidro-3´h-espiro[ciclohexan-1,1´-pirano[3,4,b] indol]-4-amina y un anticonvulsivante.Info
- Publication number
- MX353177B MX353177B MX2014013179A MX2014013179A MX353177B MX 353177 B MX353177 B MX 353177B MX 2014013179 A MX2014013179 A MX 2014013179A MX 2014013179 A MX2014013179 A MX 2014013179A MX 353177 B MX353177 B MX 353177B
- Authority
- MX
- Mexico
- Prior art keywords
- pyrano
- indol
- spiro
- dihydro
- cyclohexane
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
La presente invención se relaciona con una composición farmacéutica que comprende un primer ingrediente farmacológicamente activo seleccionado de (1r,4r)-6´-fluoro-N,N-di metil-4-fenil-4´,9´-dihidro-3´H-espiro[ciclohexan-1,1´-pirano[3,4 ,b]indol]-4-amina y las sales fisiológicamente aceptables del mismo, y un segundo ingrediente farmacológicamente activo que es un anticonvulsivante seleccionado del grupo que consiste de retigabina, lamotrigina, lacosamida, levetiracetam, carbamazepina, sultiama, fenacemida, felbamato, topiramato, feneturida, brivaracetam, selectracetam, zonisamida, estiripentol, beclamida, mexiletina, ralfinamida, metilfenobarbital, fenobarbital, primidona, barbexaclona, metarbital, etotoina, fenitoína, ácido amino (difenilhidantoina) valérico, mefenitoína, fas fenitoína, parametadiona, trimetadiona, etadiona, etosuximida, fensuximida, mesuximida, clonazepam, lorazepam, diazepam, clobazam, oxcarbazepina, eslicarbazepina, rufinamida, ácido vaiproico, valpromida, ácido ?-aminobutirico, progabida, tiagabina y las sales fisiológicamente aceptables de los mismos.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP12003898 | 2012-05-18 | ||
EP13159330 | 2013-03-15 | ||
PCT/EP2013/001471 WO2013170972A1 (en) | 2012-05-18 | 2013-05-16 | Pharmaceutical composition comprising (1r,4r)-6'-fluoro-n,n-dimethyl-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano [3,4,b]indol]-4-amine and an anticonvulsant |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2014013179A MX2014013179A (es) | 2015-01-19 |
MX353177B true MX353177B (es) | 2018-01-05 |
Family
ID=48446244
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2014013179A MX353177B (es) | 2012-05-18 | 2013-05-16 | Composicion farmaceutica que comprende (1r,4r)-6´-fluoro-n,n-dimet il-4-fenil-4´,9´-dihidro-3´h-espiro[ciclohexan-1,1´-pirano[3,4,b] indol]-4-amina y un anticonvulsivante. |
Country Status (21)
Country | Link |
---|---|
US (1) | US9345689B2 (es) |
EP (1) | EP2852384B1 (es) |
JP (1) | JP6116679B2 (es) |
CN (1) | CN104284656A (es) |
AU (1) | AU2013262078B2 (es) |
CA (1) | CA2873871A1 (es) |
CY (1) | CY1118634T1 (es) |
DK (1) | DK2852384T3 (es) |
EA (1) | EA029767B1 (es) |
ES (1) | ES2624220T3 (es) |
HK (1) | HK1204937A1 (es) |
HR (1) | HRP20170517T1 (es) |
HU (1) | HUE031984T2 (es) |
IL (1) | IL235654A (es) |
LT (1) | LT2852384T (es) |
MX (1) | MX353177B (es) |
PL (1) | PL2852384T3 (es) |
PT (1) | PT2852384T (es) |
RS (1) | RS55905B1 (es) |
SI (1) | SI2852384T1 (es) |
WO (1) | WO2013170972A1 (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6673924B2 (ja) | 2015-01-23 | 2020-03-25 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | 肝機能障害および/または腎機能障害を有する対象における疼痛を治療するためのセブラノパドール |
EP3419621A4 (en) * | 2016-02-26 | 2019-10-30 | The Johns Hopkins University | PHARMACOLOGICAL MODULATORS OF NAV1.1 VOLTAGE-CONTROLLED SODIUM CHANNELS ASSOCIATED WITH MECHANICAL PAIN |
US20190125725A1 (en) * | 2016-05-12 | 2019-05-02 | Jubilant Generics Limited | Pharmaceutical compositions comprising brivaracetam |
AU2017371467B2 (en) * | 2016-12-06 | 2023-06-01 | Jan Marius KEPPEL HESSELINK | Topical phenytoin for use in the treatment of peripheral neuropathic pain |
EP3826610A4 (en) * | 2018-07-24 | 2022-05-04 | Zenvision Pharma LLP | SYSTEM FOR NASAL DRUG DELIVERY OF BRIVARACETAM OR A SALT THEREOF |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4389393A (en) | 1982-03-26 | 1983-06-21 | Forest Laboratories, Inc. | Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose |
US4783337A (en) | 1983-05-11 | 1988-11-08 | Alza Corporation | Osmotic system comprising plurality of members for dispensing drug |
US4612008A (en) | 1983-05-11 | 1986-09-16 | Alza Corporation | Osmotic device with dual thermodynamic activity |
US4765989A (en) | 1983-05-11 | 1988-08-23 | Alza Corporation | Osmotic device for administering certain drugs |
US5708035A (en) | 1991-02-04 | 1998-01-13 | Sepracor Inc. | Methods of use and compositions of R(-) fluoxetine |
US5472711A (en) | 1992-07-30 | 1995-12-05 | Edward Mendell Co., Inc. | Agglomerated hydrophilic complexes with multi-phasic release characteristics |
US5330761A (en) | 1993-01-29 | 1994-07-19 | Edward Mendell Co. Inc. | Bioadhesive tablet for non-systemic use products |
US5455046A (en) | 1993-09-09 | 1995-10-03 | Edward Mendell Co., Inc. | Sustained release heterodisperse hydrogel systems for insoluble drugs |
US5399362A (en) | 1994-04-25 | 1995-03-21 | Edward Mendell Co., Inc. | Once-a-day metoprolol oral dosage form |
US20030056896A1 (en) * | 1995-05-12 | 2003-03-27 | Frank Jao | Effective therapy for epilepsies |
US6117900A (en) | 1999-09-27 | 2000-09-12 | Asta Medica Aktiengesellschaft | Use of retigabine for the treatment of neuropathic pain |
US8637512B2 (en) | 2002-07-29 | 2014-01-28 | Glaxo Group Limited | Formulations and method of treatment |
DE10252667A1 (de) * | 2002-11-11 | 2004-05-27 | Grünenthal GmbH | Spirocyclische Cyclohexan-Derivate |
PT1567164E (pt) | 2002-11-26 | 2009-03-31 | Alexza Pharmaceuticals Inc | Utilização de loxapina para o fabrico de um medicamento para o tratamento da dor |
US20040222123A1 (en) * | 2003-05-06 | 2004-11-11 | Barr Laboratories, Inc. | Kit for pharmaceuticals |
CN1245379C (zh) | 2003-10-30 | 2006-03-15 | 曹桂东 | 加巴喷丁的制法 |
DE10360792A1 (de) | 2003-12-23 | 2005-07-28 | Grünenthal GmbH | Spirocyclische Cyclohexan-Derivate |
GB0412878D0 (en) | 2004-06-09 | 2004-07-14 | Pfizer Ltd | Use |
AU2005256944A1 (en) | 2004-06-09 | 2006-01-05 | Pfizer Inc. | Use of reboxetine for the treatment of pain |
US8093408B2 (en) | 2005-06-21 | 2012-01-10 | The Company Wockhardt | Antidepressant oral pharmaceutical compositions |
US20080014264A1 (en) | 2006-07-13 | 2008-01-17 | Ucb, S.A. | Novel pharmaceutical compositions comprising levetiracetam |
DE102006046745A1 (de) | 2006-09-29 | 2008-04-03 | Grünenthal GmbH | Gemischte ORL1/µ-Agonisten zur Behandlung von Schmerz |
JP2008106028A (ja) * | 2006-10-26 | 2008-05-08 | Boehringer Ingelheim Internatl Gmbh | 慢性疼痛の治療におけるフリバンセリンの使用 |
US20080153874A1 (en) | 2006-12-22 | 2008-06-26 | Allergan Inc. | Alpha-2b receptor agonist and anticonvulsant compositions for treating chronic pain |
WO2008108639A1 (en) | 2007-03-08 | 2008-09-12 | Avantium Holding B.V. | Co-crystalline forms of carbamazepine |
EP1977744A1 (en) | 2007-04-03 | 2008-10-08 | Chemo Ibérica, S.A. | Polymorphic Form alpha of (S)-Pregabalin and process for its preparation |
DK2244703T3 (da) * | 2007-12-21 | 2011-12-05 | Horizon Pharma Ag | Lægemiddel og fremstillingen og anvendelse deraf i behandlingen af smertefulde neuropatier |
EP2297092A1 (en) | 2008-05-28 | 2011-03-23 | Pliva Hrvatska D.O.O. | Polymorphic and amorphous forms of lacosamide and amorphous compositions |
PE20110291A1 (es) * | 2008-09-05 | 2011-06-04 | Gruenenthal Chemie | Combinacion farmaceutica de 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol y un antiepileptico |
DE102009013613A1 (de) | 2009-03-17 | 2010-09-23 | Ratiopharm Gmbh | Trockenverarbeitung von Retigabin |
NZ605887A (en) * | 2010-08-04 | 2014-08-29 | Gruenenthal Gmbh | Pharmaceutical dosage form comprising 6’-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4’,9’-dihydro-3’h-spiro[cyclohexane-1,1’-pyrano[3,4,b]indol]-4-amine for the treatment of neuropathic pain |
CA2804077C (en) * | 2010-08-04 | 2018-09-11 | Gruenenthal Gmbh | Pharmaceutical dosage form comprising 6'-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine |
CA2802767C (en) * | 2010-08-04 | 2019-08-13 | Gruenenthal Gmbh | Pharmaceutical dosage form comprising 6'-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine |
-
2013
- 2013-05-13 US US13/892,751 patent/US9345689B2/en active Active
- 2013-05-16 PL PL13723004T patent/PL2852384T3/pl unknown
- 2013-05-16 RS RS20170381A patent/RS55905B1/sr unknown
- 2013-05-16 AU AU2013262078A patent/AU2013262078B2/en not_active Ceased
- 2013-05-16 MX MX2014013179A patent/MX353177B/es active IP Right Grant
- 2013-05-16 EP EP13723004.1A patent/EP2852384B1/en active Active
- 2013-05-16 WO PCT/EP2013/001471 patent/WO2013170972A1/en active Application Filing
- 2013-05-16 CN CN201380025637.XA patent/CN104284656A/zh active Pending
- 2013-05-16 LT LTEP13723004.1T patent/LT2852384T/lt unknown
- 2013-05-16 JP JP2015511958A patent/JP6116679B2/ja active Active
- 2013-05-16 EA EA201401271A patent/EA029767B1/ru not_active IP Right Cessation
- 2013-05-16 DK DK13723004.1T patent/DK2852384T3/en active
- 2013-05-16 HU HUE13723004A patent/HUE031984T2/en unknown
- 2013-05-16 CA CA2873871A patent/CA2873871A1/en not_active Abandoned
- 2013-05-16 ES ES13723004.1T patent/ES2624220T3/es active Active
- 2013-05-16 SI SI201330569A patent/SI2852384T1/sl unknown
- 2013-05-16 PT PT137230041T patent/PT2852384T/pt unknown
-
2014
- 2014-11-12 IL IL235654A patent/IL235654A/en active IP Right Grant
-
2015
- 2015-06-11 HK HK15105568.4A patent/HK1204937A1/xx not_active IP Right Cessation
-
2017
- 2017-02-15 CY CY20171100205T patent/CY1118634T1/el unknown
- 2017-03-30 HR HRP20170517TT patent/HRP20170517T1/hr unknown
Also Published As
Publication number | Publication date |
---|---|
JP6116679B2 (ja) | 2017-04-19 |
HK1204937A1 (en) | 2015-12-11 |
CY1118634T1 (el) | 2017-07-12 |
HUE031984T2 (en) | 2017-08-28 |
LT2852384T (lt) | 2017-04-25 |
DK2852384T3 (en) | 2017-05-08 |
EA201401271A1 (ru) | 2015-05-29 |
CN104284656A (zh) | 2015-01-14 |
AU2013262078A1 (en) | 2015-01-22 |
ES2624220T3 (es) | 2017-07-13 |
EP2852384B1 (en) | 2017-02-01 |
WO2013170972A1 (en) | 2013-11-21 |
MX2014013179A (es) | 2015-01-19 |
PL2852384T3 (pl) | 2017-09-29 |
HRP20170517T1 (hr) | 2017-06-02 |
CA2873871A1 (en) | 2013-11-21 |
EA029767B1 (ru) | 2018-05-31 |
PT2852384T (pt) | 2017-05-10 |
EP2852384A1 (en) | 2015-04-01 |
IL235654A (en) | 2017-07-31 |
SI2852384T1 (sl) | 2017-04-26 |
IL235654A0 (en) | 2015-01-29 |
RS55905B1 (sr) | 2017-09-29 |
AU2013262078B2 (en) | 2017-10-26 |
US20130317009A1 (en) | 2013-11-28 |
US9345689B2 (en) | 2016-05-24 |
JP2015516452A (ja) | 2015-06-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX353177B (es) | Composicion farmaceutica que comprende (1r,4r)-6´-fluoro-n,n-dimet il-4-fenil-4´,9´-dihidro-3´h-espiro[ciclohexan-1,1´-pirano[3,4,b] indol]-4-amina y un anticonvulsivante. | |
CY1119474T1 (el) | Κρυσταλλικες μορφες 5-χλωρο-ν2-(2-ισοπροποξυ-5-μεθυλ-4-πιπεριδιν-4-υλ-φαινυλ)-ν4[2-(προπανο-2-σουλφονυλ)-φαινυλ]-πυριμιδιν-2,4-διαμινης | |
EP2114925B8 (en) | Azetidine analogues of nucleosidase and phosphorylase inhibitors | |
BR112014009851A8 (pt) | moduladores de receptor de nmda e usos dos mesmos | |
MY160728A (en) | Morpholinothiazoles as alpha 7 positive allosteric modulators | |
MY156822A (en) | Indole derivatives as s1p1 receptor agonists | |
EA201370066A1 (ru) | Модуляторы эстрогеновых рецепторов и их применение | |
MX2010008035A (es) | Composicion que comprende anticuerpo que se fija al dominio ii de her2, y sus variantes acidas. | |
MX2019001095A (es) | Proteinas de dominio de armazon basadas en fibronectina que se unen a la proteina convertasa subtilisina kexina tipo q (pcsk9). | |
IL196280A0 (en) | Use of ampk-activating imidazole derivatives, preparation process therefor and pharmaceutical compositions comprising them | |
MX2012006430A (es) | Preparaciones de combinacion que comprenden un antagonista de citocina y un corticosteroide. | |
SI2150538T1 (sl) | Novi substituirani hidantoini | |
EA017091B9 (ru) | Фумаратная соль (альфа s, бета r)-6-бром-альфа-[2-(диметиламино)этил]-2-метокси-альфа-1-нафталенил-бета-фенил-3-хинолинэтанола | |
EA201170659A1 (ru) | Антитела к рецептору ii tgf-вета | |
TN2012000147A1 (en) | 2-oxo-1-pyrrolidinyl imidazothiadiazole derivatives | |
TN2011000651A1 (en) | Solid pharmaceutical fixed dose compositions comprising irbesartan and amlodipine their preparation and their therapeutic application | |
SG11201903770UA (en) | Combination treatments comprising imidazopyrazinones for the treatment of psychiatric and/or cognitive disorders | |
CL2013000962A1 (es) | Metodo para porducir un copolimero de carboximetilcelulosa sodica con un grado de sustitucion de 0,35 a 0,80 y gosipol; composicion farmaceutica; combinacion que lo comprende junto a uno o mas medicamentos neurolepticos, antidepresivos o anticonvulsivos; metodo de tratamiento; y uso en trastornos autistas y alteraciones cognitivas. | |
AU6435700A (en) | Cyclic peptidomimetic urokinase receptor antagonists | |
EP2547203A4 (en) | CCR5 MODULATORS FOR HIV TREATMENT | |
IL197769A (en) | The history of morphine, medicinal preparations containing them and their use in the preparation of pain medication | |
WO2010064792A3 (ko) | 푸코이단을 함유하는 골 형성 촉진 및 활성용 약학 조성물 | |
PT2496555E (pt) | Enantiómero 4r,5s de -2-(5-metil-2-oxo-4-fenil-pirrolidin- 1-il)-acetamida com actividade nootrópica | |
MX2014007547A (es) | Combinacion de (3s,3s') 4,4'-disulfandiilbis(acido 3-aminobutan 1-sulfonico) y un segundo agente antihipertensivo. | |
DE602008002027D1 (de) | Additionssalze von Hemmern des Angiotensin konvertierenden Enzyms mit NO abgebenden Säuren, Verfahren zu ihrer Herstellung und die sie enthaltenden pharmazeutischen Zusammensetzungen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |